<DOC>
	<DOCNO>NCT00496860</DOCNO>
	<brief_summary>This Phase 1 , open-labeled , non-randomized , multi-center , competitive enrollment dose-escalation study ALT-801 , study drug . The purpose study evaluate safety , determine maximum-tolerated dose ( MTD ) characterize pharmacokinetic profile ALT-801 previously treat patient progressive metastatic malignancy . ALT-801 , recombinant fusion protein interleukin-2 ( IL-2 ) component , target mechanism recognize tumor cell specific tumor marker .</brief_summary>
	<brief_title>Safety Efficacy Study ALT-801 Treat Progressive Metastatic Malignancies</brief_title>
	<detailed_description>Most current cancer treatment strategy involve use chemotherapeutic biological drug exhibit variable efficacy considerable toxicity . The limitation often result adverse side effect therapeutic drug normal tissue . One approach control effect target therapy tumor site . Of identified tumor antigen , human p53 tumor suppressor protein overexpressed wide range human malignancy . p53 intracellular tumor suppressor protein act arrest proliferation cell . When mutate , lose ability suppress abnormal proliferation exhibit longer half-life wild-type protein , allow accumulation tumor . In addition , p53 overexpression correlate tumor transformation aggression associate low overall survival rate resistance chemotherapeutic intervention cancer patient . Therefore , p53 appear marker considerable number human malignancy represent good target immunotherapeutics . However , p53 use target antibody display independently cell surface . Instead , p53 protein process intracellularly peptide fragment display cell surface context major histocompatibility complex ( MHC ) . These peptide/MHC complex recognize T-cells via T-cell receptor ( TCRs ) . Recently confirm peptide fragment significantly elevate wide range human tumor tissue , particularly melanoma , renal , lung , breast , colorectal , bladder , ovary , stomach , esophagus , lymphoma , liver , leukemia , head &amp; neck cancer . Targeted approach concentrate therapeutic cytokine tumor sit express p53 could provide considerable advantage current treatment . Interleukin-2 ( IL-2 ) well-characterized growth factor immune effector cell play critical role tumor control rejection . A recombinant human IL-2 approve treat metastatic melanoma renal cell carcinoma . However , major drawback IL-2 therapy severe systemic toxicity . As result , use high dose IL-2 limit specialized program experience personnel generally offer patient responsive excellent organ function . Thus , critical need innovative strategy enhance effect IL-2 reduce toxicity without compromise clinical benefit . The study drug , ALT-801 , biologic compound compose interleukin-2 ( IL-2 ) genetically fuse humanize soluble T-cell receptor direct p53-derived antigen . This study evaluate whether direct IL-2 activity use ALT-801 patient 's tumor sit overexpress p53 result clinical benefit . The study drug administer bolus intravenous infusion in-patient hospital set supervision qualify physician experience use anti-cancer agent include high dose IL-2 . An intensive care facility specialist skilled cardiopulmonary intensive care medicine must available . There two treatment cycle . For treatment cycle , patient admit hospital , remain hospital study drug infusion period , discharged hospital day last infusion Principal Investigator 's discretion . There 10-day resting period treatment cycle . Tumor assessment do week 7 11 start study drug .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>ENTRY CRITERIA : DISEASE CHARACTERISTICS : Locally advance metastatic malignancy Histologically cytologically confirm Evaluable Surgically medically incurable Not respond standard therapy standard therapy exist Human leukocyte antigen ( HLA ) A2.1/p53 positive PRIOR/CONCURRENT THERAPY : No prior Proleukin therapy within one year No concurrent radiotherapy , chemotherapy , immunotherapy More 4 week since prior major radiotherapy More 4 week since prior cytotoxic therapy More 6 week since prior nitrosoureas therapy More 8 week since prior monoclonal antibody therapy PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month Performance status Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Bone marrow reserve Absolute neutrophil count ( AGC/ANC ) ≥ 1,500/microliters ( uL ) Platelets ≥100,000/uL Hemoglobin ≥ 10g/dL Renal function Serum creatinine ≤ 1.5 X Upper limit normal ( ULN ) Hepatic function Total bilirubin ≤ 1.5 X ULN Aspartate Aminotransferase ( AST ) ≤ 2.5 X ULN Alkaline phosphatase ≤ 2.5 X ULN Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 1.5 X ULN Activated partial thromboplastin time ( aPTT ) ≤ 1.5 X ULN Cardiovascular May safely taper antihypertensive currently antihypertensives New York Heart Association classification I II No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia Normal cardiac stress test require following present : Over age 50 History abnormal EKG Symptoms cardiac ischemia arrhythmia Pulmonary Normal pulmonary function test ( FEV1 ≥ 75 % predict value ) follow present : Prolonged history cigarette smoking Symptoms respiratory dysfunction Other No know autoimmune disease No known HIV positive No psychiatric illness/social situation would limit study compliance No history evidence central nervous system ( CNS ) disease No active systemic infection require parental antibiotic therapy No systemic steroid therapy require No prior organ allograft Not receive investigational agent Not receive chronic medication asthma Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>p53</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>target</keyword>
	<keyword>metastatic</keyword>
	<keyword>malignancy</keyword>
	<keyword>malignancy</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>fusion protein</keyword>
	<keyword>antitumor</keyword>
	<keyword>melanoma</keyword>
	<keyword>renal cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>breast tumor</keyword>
	<keyword>cancer head neck</keyword>
	<keyword>esophagus cancer</keyword>
	<keyword>lymphoma</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>ovary cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>stomach cancer</keyword>
	<keyword>TCR</keyword>
	<keyword>T-cell receptor</keyword>
	<keyword>P53 gene</keyword>
	<keyword>p53 tumor suppressor protein</keyword>
</DOC>